Herein we explored combinations of TLR5 agonists and immune checkpoint therapy (ICT) using the immunogenic 4T1 breast cancer solid tumor model and the poorly immunogenic B16-F10 melanoma tumor model, both highly aggressive cancers and refractory to standard therapies47–49. The gene discussed is TLR5; the disease is breast carcinoma.